Alyeska Investment Group L.P. Sells 438,655 Shares of Boston Scientific Corporation $BSX

Key Points

• Alyeska Investment Group L.P. reduced its stake in Boston Scientific Corporation by 26.7%, selling 438,655 shares and maintaining ownership of 1,202,779 shares valued at $121.3 million.
• Boston Scientific reported a quarterly EPS of $0.75, surpassing estimates, with a 22.8% revenue increase from the same period last year, reaching $5.06 billion.
• Insider activity included sales by EVP Joseph Michael Fitzgerald and Director Edward J. Ludwig, with insiders selling a total of 124,214 shares valued at over $13 million in the last quarter.

Alyeska Investment Group L.P. decreased its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 26.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,202,779 shares of the medical equipment provider's stock after selling 438,655 shares during the quarter. Alyeska Investment Group L.P. owned 0.08% of Boston Scientific worth $121,336,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in BSX. Brighton Jones LLC lifted its stake in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares during the period. Bank Pictet & Cie Europe AG raised its position in shares of Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares during the period. Highview Capital Management LLC DE raised its position in shares of Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after purchasing an additional 1,439 shares during the period. Aptus Capital Advisors LLC raised its position in shares of Boston Scientific by 17.3% during the fourth quarter. Aptus Capital Advisors LLC now owns 11,692 shares of the medical equipment provider's stock worth $1,044,000 after purchasing an additional 1,723 shares during the period. Finally, Algert Global LLC acquired a new stake in shares of Boston Scientific during the fourth quarter worth about $297,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Down 0.1%

Boston Scientific stock traded down $0.15 during midday trading on Friday, reaching $107.14. The stock had a trading volume of 4,062,436 shares, compared to its average volume of 5,787,252. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm's fifty day simple moving average is $104.77 and its 200-day simple moving average is $102.20. The stock has a market capitalization of $158.76 billion, a P/E ratio of 63.78, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's revenue was up 22.8% compared to the same quarter last year. During the same period last year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $18,397,457 in the last ninety days. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Robert W. Baird raised their price target on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Wells Fargo & Company lifted their target price on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. UBS Group lifted their target price on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Finally, Raymond James Financial lifted their target price on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.